- Home
- ATIP vs PIRS Comparison
ATIP vs PIRS Comparison
Compare ATIP & PIRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATIP
- PIRS
- Stock Information
- Founded
- ATIP 1996
- PIRS 2001
- Country
- ATIP United States
- PIRS United States
- Employees
- ATIP N/A
- PIRS N/A
- Industry
- ATIP Hospital/Nursing Management
- PIRS Biotechnology: Pharmaceutical Preparations
- Sector
- ATIP Health Care
- PIRS Health Care
- Exchange
- ATIP Nasdaq
- PIRS Nasdaq
- Market Cap
- ATIP 26.0M
- PIRS 21.3M
- IPO Year
- ATIP N/A
- PIRS N/A
- Fundamental
- Price
- ATIP $6.24
- PIRS $16.96
- Analyst Decision
- ATIP
- PIRS
- Analyst Count
- ATIP 0
- PIRS 0
- Target Price
- ATIP N/A
- PIRS N/A
- AVG Volume (30 Days)
- ATIP 7.9K
- PIRS 6.3K
- Earning Date
- ATIP 11-04-2024
- PIRS 11-12-2024
- Dividend Yield
- ATIP N/A
- PIRS N/A
- EPS Growth
- ATIP N/A
- PIRS N/A
- EPS
- ATIP N/A
- PIRS N/A
- Revenue
- ATIP $717,149,000.00
- PIRS $20,872,000.00
- Revenue This Year
- ATIP $10.99
- PIRS N/A
- Revenue Next Year
- ATIP $5.98
- PIRS N/A
- P/E Ratio
- ATIP N/A
- PIRS N/A
- Revenue Growth
- ATIP 11.00
- PIRS N/A
- 52 Week Low
- ATIP $3.92
- PIRS $6.20
- 52 Week High
- ATIP $8.48
- PIRS $23.20
- Technical
- Relative Strength Index (RSI)
- ATIP 60.27
- PIRS 56.96
- Support Level
- ATIP $5.66
- PIRS $16.09
- Resistance Level
- ATIP $6.46
- PIRS $16.55
- Average True Range (ATR)
- ATIP 0.30
- PIRS 0.29
- MACD
- ATIP 0.01
- PIRS 0.03
- Stochastic Oscillator
- ATIP 72.50
- PIRS 100.00
About ATIP ATI Physical Therapy Inc.
ATI Physical Therapy Inc is a recognized outpatient physical therapy provider in the United States specializing in outpatient rehabilitation and adjacent healthcare services. It offer a variety of services within the clinics, including physical therapy to treat spine, shoulder, knee and neck injuries or pain; work injury rehabilitation services, including work conditioning and work hardening; hand therapy; and other specialized treatment services.
About PIRS Pieris Pharmaceuticals Inc.
Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store, and transport a wide spectrum of molecules. The Company's clinical pipeline consists of immuno-oncology, or IO, bispecifics in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Geographically, all the operations of the firm function through the region of the United States.